Managers / Q3 2025 · view latest →
Foresite Capital Management VI LLC
CIK 0002013341 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management Vi LLC reported $259M in U.S.-listed holdings across 12 positions for Q3 2025.
The portfolio is heavily concentrated: CGON alone accounts for 34.6% of reported value.
Compared with Q2 2025, the fund opened 1 new position and exited 9.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 87.1% · $225M
- ADR · 12.3% · $32M
- Other · 0.6% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| DNLIDenali Therapeutics Inc. | NEW | +1.00M | 1.00M | +$15M | $15M |
| VSTMVerastem, Inc. | ADDED | +1.34M | 2.62M | +$18M | $23M |
| BCAXBicara Therapeutics Inc | SOLD OUT | −949.3K | 0 | −$9M | $0 |
| EWTXEdgewise Therapeutics Inc | SOLD OUT | −585.0K | 0 | −$8M | $0 |
| XENEXenon Pharmaceuticals Inc | SOLD OUT | −160.0K | 0 | −$5M | $0 |
| CGEMCullinan Therapeutics Inc | SOLD OUT | −594.0K | 0 | −$4M | $0 |
| GPCRStructure Therapeutics Inc | SOLD OUT | −210.0K | 0 | −$4M | $0 |
| ALLOAllogene Therapeutics Inc | SOLD OUT | −2.88M | 0 | −$3M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CGONCG Oncology, Inc.history → | COM | 34.57% | $89M | 2.22M |
| 2 | RAPTRAPT Therapeutics, Inc.history → | COM | 15.57% | $40M | 1.56M |
| 3 | 260Centessa Pharmaceuticals plchistory → | SPONSORED ADS | 12.31% | $32M | 1.31M |
| 4 | VSTMVerastem, Inc.history → | COM | 8.92% | $23M | 2.62M |
| 5 | ALMSALUMIS INC.history → | COM | 6.55% | $17M | 4.25M |
| 6 | DNLIDenali Therapeutics Inc.history → | COM | 5.61% | $15M | 1.00M |
| 7 | CRVSCorvus Pharmaceuticals, Inc.history → | COM | 4.93% | $13M | 1.73M |
| 8 | AKROAkero Therapeutics, Inc.history → | COM | 4.49% | $12M | 244.9K |
| 9 | KYMRKymera Therapeutics, Inc.history → | COM | 3.20% | $8M | 146.3K |
| 10 | HNGEHinge Health, Inc.history → | CL A | 2.56% | $7M | 135.0K |
| 11 | RNAGBPAvidity Biosciences, Inc. | COM | 0.67% | $2M | 40.0K |
| 12 | CASI Pharmaceuticals, Inc. | ORD SHS | 0.63% | $2M | 980.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $460M | 17 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $331M | 12 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $259M | 12 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $178M | 20 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $183M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $224M | 14 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.